Ignite Creation Date:
2025-12-24 @ 10:50 PM
Ignite Modification Date:
2026-01-01 @ 9:22 PM
Study NCT ID:
NCT03203369
Status:
TERMINATED
Last Update Posted:
2019-07-31
First Post:
2017-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
Sponsor:
Cellectis S.A.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Blastic plasmacytoid dendritic cell neoplasm | View |
| None | Natural Killer (NK) cell blastic lymphoma | View |
| None | Hematologic malignancies | View |
| None | Cluster of differentiation (CD) CD4+CD56+ hematodermic tumor | View |
| None | Acute leukemia and myeloid neoplasms | View |
| None | Chimeric Antigen Receptor T-cell (CAR-T) therapy | View |
| None | Allogeneic | View |
| None | Cluster of differentiation 4 (CD4) | View |
| None | Cluster of differentiation 56 (CD56) | View |